about Us

Background

The global challenges of multidrug-resistant microbial pathogens and the evolution of SARS- CoV-2, in an ever-expanding population of immunocompromised patients with cancer, transplantation, autoimmune diseases, and other immunodeficiencies require new integrated strategies of novel immunotherapeutics, antimicrobial therapy, and rapid molecular diagnostics. These strategies are essential for being able to combat life-threatening infections in our immunocompromised host populations. Therefore, a new center is being established in order to provide a powerful engine of translational research from pre-clinical studies to patient-oriented clinical trials for the diagnosis, treatment, and prevention of life-threatening infections in immunocompromised patients with cancer: Center for Innovative Therapeutics and Diagnostics

Mission

The mission of the Center for Innovative Therapeutics and Diagnostics is to mentor the next generation of clinicians and scientists to develop, investigate, and implement leading-edge technologies for novel immunotherapeutics, new antimicrobial agents, and advanced molecular detection systems for the diagnosis, treatment, and prevention of life-threatening infections in immunocompromised pediatric and adult patients with cancer, transplantation, autoimmune diseases, and other immunodeficiencies.

Organizational Structure

The Center for Innovative Therapeutics and Diagnostics (CITD) will be organized under the Office of the Director that oversees, supports, and coordinates the Translational Research Laboratory and Clinical Research Office.

Mentoring and Teaching
Mentoring, teaching, supporting, and inspiring the next generation of physicians, scientists, microbiologists, medical mycologists, pharmacists, nurses, and technologists in the battle against life-threatening infections in immunocompromised patients is a vital arm of the Center’s mission. Dr. Walsh has mentored more than 200 students, residents, post-doctoral fellows, microbiologists, medical mycologists, pharmacists, immunologists, nurses, technologists, and junior faculty from 39 different countries in the fields of Medical Mycology, Microbiology, Immunology, Pharmacology, and Infectious Diseases.  Sixty-two mentees are members of historically disadvantaged minorities and 116 are women. Many are now emerging or established leaders, including program directors, division chiefs, and department chairs, in the fields of antimicrobial pharmacology, antifungal therapeutics, medical mycology, host defenses, clinical microbiology, immunology, and infectious diseases with particular focus on invasive fungal infections and multidrug resistant bacterial infections, as Associate Professors or full Professors of Pediatrics, Medicine, Pathology, Microbiology, Immunology, and Pharmacy in leading universities, while other mentees have achieved important leadership roles in the government agencies.

Translational Research Laboratory (TRL)
Designs, organizes, conducts, and reports in vitroex vivo, and in vivo preclinical investigations of novel immunotherapeutics, new antimicrobial agents, and innovative molecular diagnostics; prepares reports for IND and NDA applications in conjunction with collaborators.

Clinical Research Unit (CRU)
Designs, organizes, conducts, and reports clinical investigations of new antimicrobial agents, immunotherapeutic molecules, and molecular diagnostic platforms arising from the TRL and from external collaborators; develops, implements, submits, and monitors clinical protocols through initiation to completion; prepares reports for IND and NDA applications in conjunction with collaborators.

Supportive Care of Patients with Cancer, Transplantation, and Immunodeficiencies
The Center serves as an engine of innovation and translational research for Supportive Care for patients cancer, transplantation, and immunodeficiencies, especially in augmentation of innate systemic and mucosal host defenses, hematopoietic recovery, treatment of MDR pathogens, and rapid molecular diagnosis.

Collaborations
The Translational Research Laboratory and the Clinical Research Unit collaborate with university partners, industrial scientists, government agencies, philanthropic organizations, and foundations in order to achieve the Center’s life-saving mission.

Resources
Resources for the Center consists of grants and contracts from industrial collaborations, government agencies, and foundation partnerships, as well as critical contributions from philanthropic supporters.

Staff

Office of the Director
Director: Thomas J. Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM

Administrative Support
Administrative Assistant 1: Jeniffer Rabb
Administrative Assistant 2: TBD
Administrative Assistant 3: TBD

Translational Research Laboratory
Senior Laboratory Director for Immunotherapeutics: Emmanuel Roilides, MD, PhD

The Laboratory will be initially supported by five technologists: TBD

Two doctoral fellows: Panagiotis Zagaliotis, MS; Povilas Kavaliauskas, MS,
Two post-doctoral fellows: TBD
Four senior scientists: Maria Simitsopoulou, PhD; Anthi Petrou PhD; Ioannis Vizirianakis PhD; Athina Geronikaki, PhD

Clinical Research Office
Associate Director: TBD
Clinical Research Scholar: TBD Regulatory Coordinator: TBD Protocol Development Manager: TBD Study Reporting Manager: TBD
Data manager: TBD
Research nurses: TBD
Research assistants: TBD